Department of Haematology, University College London Hospitals NHS Foundation Trust and UCL Medical School, London, UK.
Br J Haematol. 2013 May;161(4):578-86. doi: 10.1111/bjh.12294. Epub 2013 Mar 18.
The use of allogeneic haematopoietic stem cell transplantation (Allo-HSCT) is a standard treatment option for many patients with haematological malignancies. Historically, patients requiring intensive care unit (ICU) admission for transplant-related toxicities have fared extremely poorly, with high ICU mortality rates. Little is known about the impact of reduced intensity Allo-HSCT conditioning regimens in older patients on the ICU and subsequent long-term outcomes. A retrospective analysis of data collected from 164 consecutive Allo-HSCT recipients admitted to ICU for a total of 213 admissions, at a single centre over an 11·5-year study period was performed. Follow-up was recorded until 31 March 2011. Autologous HSCT recipients were excluded. In this study we report favourable ICU survival following Allo-HSCT and, for the first time, demonstrate significantly better survival for patients who underwent Allo-HSCT with reduced intensity conditioning compared to those treated with myeloablative conditioning regimens. In addition, we identified the need for ventilation (invasive or non-invasive) as an independently significant adverse factor affecting short-term ICU outcome. For patients surviving ICU admission, subsequent long-term overall survival was excellent; 61% and 51% at 1 and 5 years, respectively. Reduced intensity Allo-HSCT patients admitted to ICU with critical illness have improved survival compared to myeloablative Allo-HSCT recipients.
同种异体造血干细胞移植(Allo-HSCT)的应用是许多血液恶性肿瘤患者的标准治疗选择。历史上,因移植相关毒性而需要入住重症监护病房(ICU)的患者预后极差,ICU 死亡率极高。对于接受减强度 Allo-HSCT 预处理方案的老年患者在 ICU 中的影响以及随后的长期预后,知之甚少。对在单一中心 11.5 年的研究期间连续收治的 164 例因移植相关毒性而总共入住 ICU 213 次的 Allo-HSCT 受者的数据进行了回顾性分析。随访记录至 2011 年 3 月 31 日。排除了自体 HSCT 受者。在这项研究中,我们报告了 Allo-HSCT 后 ICU 存活率良好,并且首次证明与接受清髓性预处理方案相比,接受减强度预处理方案的患者具有更好的生存结果。此外,我们发现需要通气(有创或无创)是影响短期 ICU 结果的独立不良因素。对于存活 ICU 入住的患者,随后的长期总生存率非常好;分别为 1 年和 5 年时的 61%和 51%。与接受清髓性 Allo-HSCT 的患者相比,因危重病而入住 ICU 的接受减强度 Allo-HSCT 的患者的存活率有所提高。